AstraZeneca COVID-19 Vaccine: Technology, Efficacy, and Global Distribution
The AstraZeneca COVID-19 vaccine, known by various names including Vaxzevria and Covishield, represents a significant milestone in global health. Developed to target the SARS-CoV-2 virus, this vaccine utilizes a viral vector platform—a method that uses a modified, harmless virus to deliver genetic instructions to the body to trigger an immune response.
![A vial of the Oxford-AstraZeneca COVID-19 vaccine produced in the Serum Institute of India (SII) as "Covishield"[3]](/images/4a/0d/4a0d4c6c16f8933de91141a6104fb3b600c73adae57adbfd58b1897127cf0ff3.jpg)
Key Facts
- Vaccine Type: Viral vector
- Target Virus: SARS-CoV-2
- Common Trade Names: Vaxzevria, Covishield
- Administration Route: Intramuscular injection
- Primary Identifiers: AZD1222, ChAdOx1 nCoV-19
Technical Specifications and Identification
The vaccine is recognized globally through several scientific identifiers. In clinical and regulatory settings, it is often referred to as AZD1222 or ChAdOx1-S. For laboratory and pharmacological tracking, it is associated with the CAS Number 2420395-83-9 and the DrugBank identifier DB15656.
In terms of medical classification, the vaccine is assigned the WHO ATC code J07BN02. Its legal status varies by region; for example, it is a prescription-only medicine (POM) in the United Kingdom and is classified as S4 in Australia.
Vaccine Efficacy Against Variants
Clinical data has measured the effectiveness of the vaccine across different levels of illness severity and various viral variants. Effectiveness is often categorized by whether the patient is asymptomatic (showing no symptoms) or symptomatic (showing symptoms), as well as the prevention of hospitalization.
Efficacy Data Summary
| Doses | Severity of Illness | Alpha Variant | Delta Variant | Gamma Variant | Beta Variant |
|---|---|---|---|---|---|
| 1 Dose | Asymptomatic | 37% (32–42%) | 18% (9–25%) | 33% (32–34%) | Not reported |
| 1 Dose | Symptomatic | 39% (32–45%) | 33% (23–41%) | 33% (26–40%) | Not reported |
| 1 Dose | Hospitalization | 76% (61–85%) | 71% (51–83%) | 52% (50–53%) | Not reported |
| 2 Doses | Asymptomatic | 73% (66–78%) | 60% (53–66%) | 70% (69–71%) | Not reported |
| 2 Doses | Symptomatic | 81% (72–87%) | 61% (51–70%) | 78% (69–84%) | 10% (−77 to 55%) |
| 2 Doses | Hospitalization | 86% (53–96%) | 92% (75–97%) | 87% (85–88%) | Not reported |
Global Distribution and Approvals
The rollout of the AstraZeneca vaccine was a massive international undertaking. Various countries and organizations secured significant quantities of doses to combat the pandemic.
Major Distribution Milestones
- United Kingdom: 100 million doses (May 2020)
- United States: 300 million doses (May 2020)
- European Union: 400 million doses (August 2020)
- COVAX (WHO): 300 million doses (June 2020)
- Japan: 120 million doses (August 2020)
- Australia: 25 million doses (August 2020)
Beyond these major hubs, the vaccine received approvals and emergency use authorizations in numerous other nations, including Canada, South Korea, South Africa, Thailand, and Malaysia.
Frequently Asked Questions
What type of vaccine technology does AstraZeneca use?
The AstraZeneca vaccine is a viral vector vaccine, which uses a modified version of a different virus to deliver instructions to the immune system.
How is the vaccine administered?
The vaccine is administered via the intramuscular route, typically through an injection into the muscle.
What are the different names for this vaccine?
Depending on the region and manufacturer, it is known as Vaxzevria, Covishield, AZD1222, or ChAdOx1 nCoV-19.
Is the vaccine effective against different variants?
Clinical data shows varying levels of effectiveness against different variants, such as Alpha, Delta, Gamma, and Beta, particularly regarding the prevention of symptomatic illness and hospitalization.
What is the pregnancy category for this vaccine in Australia?
In Australia, the vaccine is classified under pregnancy category B1.